Oncology Medical Imaging Symposium Half-Day Program
8:30 am – 12:00 pm
Wednesday, March 18 — San Francisco, CA
Thursday, March 19 — San Diego, CA

Hear from the following experts:

Dr. Oliver Bohnsack, M.D., Ph.D., MBA
Medical Director, Head of Oncology Imaging
Perceptive Informatics

Jeffrey Stewart, MBA
Director of Clinical Operations
Adventrx Pharmaceuticals, Inc

George Q. Mills, M.D., MBA
Vice President, Medical Imaging Consulting
Perceptive Informatics


Please direct event questions to
Jo Sudore at jsudore@clinphone.com or call +1.609.524.4124

Registration
This symposium is open exclusively to invited pharmaceutical and biotechnology companies. Registration is complimentary.

Register

Join us for a half-day symposium that will address the difference between RECIST 1.0 and 1.1, discuss challenges for effective implementation of early phase clinical trials, and present the sponsor’s view of central imaging in clinical trials.

Register

What You Will Learn
  • RECIST 1.1: What you need to consider for your Oncology studies with imaging based endpoints
  • How the type of imaging can impact trial design, site selection and trial conduct
  • Key features and the importance of the centralized IND for investigational PET imaging biomarkers
Who Should Attend
Directors and managers from biotech and pharmaceutical companies with responsibilities or involvement in the following areas:
  • Clinical Operations
  • Imaging Operations
  • Outsourcing
  • Project Management
  • Scientific/Medical Affairs
Symposium Locations:

March 18
Marriott San Francisco Airport
1800 Old Bayshore Highway
Burlingame, CA 94010
Toll Free Reservations: (800) 228-9290
Direct Hotel Number: (650) 692-9100
Click here for hotel information
March 19
Hilton La Jolla Torrey Pines
10950 N. Torrey Pines Rd
La Jolla, CA 92037
Toll Free Reservations: (800) 445-8667
Direct Hotel Number: (858) 558-1500
Click here for hotel information
SYMPOSIUM AGENDA  
8:00 am - 8:30 am Registration and Networking Breakfast
8:30 am - 8:45 am Welcoming Remarks & Introductions
8:45 am - 9:30 am Why RECIST 1.1 and not 2.0?
Dr. Oliver Bohnsack, M.D., Ph.D. MBA
Medical Director, Head of Oncology Imaging, Perceptive Informatics
  • Why it is only RECIST 1.1 and not 2.0
  • What you need to consider for your Oncology studies with imaging based endpoints going forward
  • What's next? What else is out there?
9:30 am - 9:40 am Discussion/Q&A
9:40 am - 9:50 am Break
9:50 am - 10:35 am Central Imaging in Clinical Trials: A Sponsor Perspective
Jeffrey Stewart, MBA
Director of Clinical Operations, Adventrx Pharmaceuticals, Inc.
  • How the type of imaging can impact the trial design, site selection and trial conduct
  • Differences between site and central imaging data
  • Steps to accelerate data analysis and interpretation at the end of the study
10:35 am - 10:45 am Discussion/Q&A
10:45 am - 10:55 am Break
10:55 am - 11:40 am The Challenges and Requirements for Effective Implementation of Early Phase Clinical Trials
George Q. Mills, M.D., MBA
Vice President, Medical Imaging Consulting, Perceptive Informatics
  • Highlights of the Exploratory IND Guidance
  • Key features and importance of the centralized IND for investigational PET imaging biomarkers
  • The value of the regulatory lexicon for imaging biomarkers & surrogates
11:40 am - 11:50 am Discussion/Q&A
11:50 am - 12:00 pm Wrap-Up and Closing Remarks
   Contact Us  ::  Site Map  ::  Privacy Policy  ::  Tel. +1.866.289.4464
   ©2009 Perceptive Informatics®. All rights reserved. A PAREXEL® Company


Perceptive Informatics, Inc.  200 West Street, Waltham, MA 02451